No Data
No Data
Buy Rating Affirmed for ArriVent BioPharma on Strong Drug Trial Prospects and Strategic Advancements
ArriVent BioPharma Welcomes Dr. Hohneker to Board
Press Release: ArriVent Appoints John Hohneker, M.D., to Its Board of Directors
ArriVent BioPharma today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics.
Express News | Arrivent Appoints John Hohneker, M.d., to Its Board of Directors
Express News | HC Wainwright & Co. Reiterates Buy on ArriVent BioPharma, Maintains $25 Price Target
Buy Rating for ArriVent BioPharma Amid Strong Financials and Promising Clinical Trials
No Data